LifeStance Health Group (NASDAQ:LFST) Stock Price Target Raised at KeyCorp

Posted by Francis Steltz on Nov 7th, 2026

LifeStance Health Group (NASDAQ:LFST – Free Report) had its price target increased by KeyCorp from $15.00 to $17.00 in a research report report published on Friday,Benzinga reports. KeyCorp currently has an overweight rating on the stock.

A number of other brokerages also recently issued reports on LFST. JPMorgan Chase & Co. upped their price objective on shares of LifeStance Health Group from $9.00 to $13.00 and gave the stock a “neutral” rating in a research report on Friday, August 14th. Weiss Ratings raised LifeStance Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 11th. BTIG Research boosted their price objective on LifeStance Health Group from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Thursday. Canaccord Genuity Group raised their target price on LifeStance Health Group from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Wednesday, September 9th. Finally, Barclays lifted their target price on LifeStance Health Group from $13.00 to $15.00 and gave the stock an “overweight” rating in a research note on Thursday, September 10th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, LifeStance Health Group currently has an average rating of “Moderate Buy” and an average price target of $13.75.

Get Our Latest Stock Report on LFST

LifeStance Health Group Stock Up 2.5%

LifeStance Health Group stock traded up $0.34 during mid-day trading on Friday, reaching $13.77. The stock had a trading volume of 4,924,487 shares, compared to its average volume of 2,978,738. The firm has a market capitalization of $5.26 billion, a PE ratio of 72.48 and a beta of 1.35. LifeStance Health Group has a fifty-two week low of $5.87 and a fifty-two week high of $15.66. The stock’s 50-day simple moving average is $12.62 and its 200-day simple moving average is $9.49. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.38 and a current ratio of 1.38.

LifeStance Health Group (NASDAQ:LFST – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.04 by $0.02. The firm had revenue of $455.86 million during the quarter, compared to the consensus estimate of $431.59 million. LifeStance Health Group had a return on equity of 3.39% and a net margin of 3.19%. The firm’s revenue for the quarter was up 25.3% on a year-over-year basis. On average, sell-side analysts forecast that LifeStance Health Group will post 0.17 EPS for the current fiscal year.

Insider Buying and Selling

In other LifeStance Health Group news, CTO Vukasin Paunovich sold 42,067 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $12.87, for a total transaction of $541,402.29. Following the completion of the transaction, the chief technology officer owned 205,379 shares in the company, valued at $2,643,227.73. This trade represents a 17.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Lisa K. Miller sold 47,912 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $10.85, for a total transaction of $519,845.20. Following the completion of the sale, the chief operating officer directly owned 281,289 shares in the company, valued at approximately $3,051,985.65. This trade represents a 14.55% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 13,777,580 shares of company stock valued at $146,433,781. 3.50% of the stock is owned by insiders.

Institutional Investors Weigh In On LifeStance Health Group

A number of hedge funds and other institutional investors have recently bought and sold shares of LFST. BlackRock Inc. purchased a new position in shares of LifeStance Health Group in the second quarter valued at $389,293,000. Wellington Management Group LLP bought a new stake in shares of LifeStance Health Group during the second quarter valued at about $30,881,000. Jennison Associates LLC boosted its position in shares of LifeStance Health Group by 38.5% in the first quarter. Jennison Associates LLC now owns 10,228,801 shares of the company’s stock valued at $65,157,000 after acquiring an additional 2,843,388 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of LifeStance Health Group by 16.4% in the first quarter. Dimensional Fund Advisors LP now owns 10,367,680 shares of the company’s stock valued at $66,038,000 after acquiring an additional 1,461,215 shares during the period. Finally, Bank of America Corp DE purchased a new position in LifeStance Health Group during the second quarter valued at approximately $14,987,000. Institutional investors own 85.50% of the company’s stock.

LifeStance Health Group News Summary

Here are the key news stories impacting LifeStance Health Group this week:

Positive Sentiment: LifeStance reported Q3 adjusted earnings of $0.06 per share, ahead of estimates, and revenue of $455.9 million versus forecasts of about $431.6 million. Revenue grew 25.3% year over year, and the company raised its full-year outlook—evidence of stronger-than-expected performance. LifeStance Q3 results and outlook
Positive Sentiment: Analysts raised their targets and maintained bullish ratings: KeyCorp lifted its target to $17 with an “overweight” rating, Canaccord Genuity raised its target to $16 with a “buy” rating, and BTIG increased its target to $20, also with a “buy” rating. These revisions signal greater optimism about potential upside. KeyCorp rating Canaccord Genuity rating BTIG target increase
Neutral Sentiment: Coverage noted LFST reached a 52-week high and highlighted its momentum, though those signals alone do not establish whether further gains are sustainable. Zacks coverage of LFST’s high

LifeStance Health Group Company Profile

(Get Free Report)

LifeStance Health Group, Inc is a provider of outpatient behavioral health services in the United States. Through a network of clinicians and care centers, the company offers mental health care through in-person appointments and telehealth visits.

LifeStance’s services include individual, couples and family therapy; psychiatric evaluation and medication management; psychological and neuropsychological testing; and treatment for conditions such as depression, anxiety, attention-deficit/hyperactivity disorder, bipolar disorder, post-traumatic stress disorder and other behavioral health concerns.